2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Psoriasis
1
Lymphoma, Follicular
1
Interventions
tofacitinib
7
Etanercept
7
Methotrexate
4
Adalimumab
4
deucravacitinib
3
secukinumab
2
apremilast
2
Nivolumab
2
sotrastaurin
1
sodium luminolate
1
purine
1
ixekizumab
1
fumaric acid
1
calcipotriene
1
cabozantinib
1
baricitinib
1
abrocitinib
1
Vitamin D
1
Vaccines
1
Sulfasalazine
1
Standard of Care
1
Specimen Handling
1
Saline Solution
1
Practice Guidelines as Topic
1
Platinum Compounds
1
Methods
1
Mesalamine
1
Mercaptopurine
1
Ipilimumab
1
Interviews as Topic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Psoriasis
×
Anti-Infective Agents, Local
×
Clear all
NCT01313221
2017-03-15
REFINE
Amgen
Phase 3
Completed
310 enrolled
32 charts